Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV
about
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemicRole of Marine Natural Products in the Genesis of Antiviral AgentsEffect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and DarunavirDesign of HIV-1 Protease Inhibitors with C3-Substituted Hexahydrocyclopentafuranyl Urethanes as P2-Ligands: Synthesis, Biological Evaluation, and Protein–Ligand X-ray Crystal StructureThe higher barrier of darunavir and tipranavir resistance for HIV-1 proteaseBurkholderia oklahomensisagglutinin is a canonical two-domain OAA-family lectin: structures, carbohydrate binding and anti-HIV activitySubstituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitorsPotent Antiviral HIV-1 Protease Inhibitor GRL-02031 Adapts to the Structures of Drug Resistant Mutants with Its P1′-Pyrrolidinone RingP2' Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran MoietyHighly Potent HIV-1 Protease Inhibitors with Novel Tricyclic P2 Ligands: Design, Synthesis, and Protein–Ligand X-ray StudiesProbing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological EvaluationUnderstanding the structural mechanisms of antibiotic resistance sets the platform for new discoveryProteochemometric modeling of the bioactivity spectra of HIV-1 protease inhibitors by introducing protein-ligand interaction fingerprintA Functional Interplay between Human Immunodeficiency Virus Type 1 Protease Residues 77 and 93 Involved in Differential Regulation of Precursor Autoprocessing and Mature Protease ActivityDrug discovery and the use of computational approaches for infectious diseases.Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.Capturing the essence of organic synthesis: from bioactive natural products to designed molecules in today's medicine.Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.Organic carbamates in drug design and medicinal chemistryDesign of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical CyclizationConserved hydrogen bonds and water molecules in MDR HIV-1 protease substrate complexes.Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.Development of anti-HIV peptides based on a viral capsid protein.Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.Experimental and computational studies on the effects of valganciclovir as an antiviral drug on calf thymus DNA.Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray StudiesStructure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studiesEnantioselective Synthesis of Cyclopentyltetrahydrofuran (Cp-THF), an Important High-Affinity P2-Ligand for HIV-1 Protease Inhibitors.Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges.A fission yeast cell-based system for multidrug resistant HIV-1 proteases.Investigational protease inhibitors as antiretroviral therapies.Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase.Role of CXCR4 in HIV infection and its potential as a therapeutic target.Role of darunavir in the management of HIV infection.Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS
P2860
Q24655011-28331F04-7872-4C0F-B6CB-FEE2C6E4957FQ26796360-D60F030B-364F-404B-8CB5-8C54207E7337Q27651021-A0FE9B31-A251-4FF8-A7B6-3FA99AB13628Q27671213-FD6DE14B-5268-48A8-9E9E-BAD1CA35C05AQ27672193-221D800D-800A-4C33-86C0-6EF1C57D8DB0Q27676767-6A23CFB7-0715-497C-92DF-6BF0CBA9961DQ27677475-6F1AB42D-E357-48C2-8ABC-60FEC5BACE27Q27677939-DCCE89FE-9F76-48C8-80E3-174DA79E6375Q27679177-5D19A9A4-2F0E-4E53-9697-F3599C9FCE2AQ27679692-AEB97091-00EB-4035-AE05-1099C88F9582Q27717366-9CD0E2E9-38EC-4C4F-A874-9E4613E39B5FQ28083259-03FFF28F-36BB-4EEA-A35B-54533B0D70FFQ28481635-A79CA8C6-A977-4F39-84EB-4BD1BC27222DQ28546560-3C53CEB4-7D29-42E3-91FE-CF1191CCA4E9Q30404272-A247FDFA-1D4A-4DB2-8367-84648A435C33Q34046931-A519AE31-EBF8-4514-8BF6-E3BC99A12CC6Q34361292-7DCF81B0-5138-42B3-A7D8-80187CD374DEQ34440391-734C040A-453C-48E1-8E30-C80D8418F3A2Q34638302-E851DC29-BF88-4902-8B83-C736FE5B3227Q35365543-0889A907-277B-4BA6-8017-133118D2DE8BQ35569236-DDFF0305-B883-4342-9C3C-91544415604CQ35846634-F7D9D7C3-4ED9-438E-A1D0-A63E0C87217EQ35903710-CE113A53-4E46-43E0-9224-12FC1F34F9C3Q35935885-17A26584-B9D3-4317-8D25-F36D4EC0C988Q36080284-F1748ED6-69BF-4658-92B1-448C59277958Q36166928-35B65750-DF52-4F59-8BCA-8DC4F070CF86Q36167461-8FB223BB-59B0-4627-A7D3-B8625B10BD36Q36338687-14DA70C5-28A6-471E-BAB8-865EC1D2D11AQ36613697-1BC8D3F4-0DB0-4BFF-AA2D-4AA8978E369AQ36613702-EDE653C6-500E-4CB5-AD5C-3E1BB15B9D5EQ36713828-3FC6DE5B-7A7E-4D00-B554-CD7FF8FDEAEAQ37415603-49E0F93B-8F76-4ADA-A45B-9DCC6D1DE925Q37578986-642B59DB-F33D-4B40-91AC-FEB922699097Q37582521-C18FA1FB-1149-43CB-91DE-B2C5B329FF3FQ37644005-D02F6790-8FAF-4B4D-B8C8-9681D5B4B71CQ37772888-99864793-EA16-474A-AE06-B74B5D1D901FQ37957871-9CD948B0-7EA0-4BCA-8826-B428336AC300Q37980084-DDFC2B5C-8DE0-4725-A034-68B3FEEA296EQ38164839-6FD7474B-AF18-4587-8CF5-F060C9A3598AQ38708006-BBC75778-7157-4CDE-95DA-112EABD12E5F
P2860
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Darunavir, a conceptually new ...... reatment of drug-resistant HIV
@ast
Darunavir, a conceptually new ...... reatment of drug-resistant HIV
@en
Darunavir, a conceptually new ...... reatment of drug-resistant HIV
@nl
type
label
Darunavir, a conceptually new ...... reatment of drug-resistant HIV
@ast
Darunavir, a conceptually new ...... reatment of drug-resistant HIV
@en
Darunavir, a conceptually new ...... reatment of drug-resistant HIV
@nl
prefLabel
Darunavir, a conceptually new ...... reatment of drug-resistant HIV
@ast
Darunavir, a conceptually new ...... reatment of drug-resistant HIV
@en
Darunavir, a conceptually new ...... reatment of drug-resistant HIV
@nl
P2093
P2860
P1476
Darunavir, a conceptually new ...... reatment of drug-resistant HIV
@en
P2093
Arun K Ghosh
Hiroaki Mitsuya
Zachary L Dawson
P2860
P304
P356
10.1016/J.BMC.2007.09.010
P407
P577
2007-12-15T00:00:00Z